Gonadotropin releasing hormone analogue and growth hormone therapy in precocious and premature puberty following cranial irradiation for acute lymphoblastic leukaemia.
Ten girls with early puberty secondary to cranial irradiation as a part of the treatment for acute lymphoblastic leukaemia (ALL) were treated with either gonadotropin-releasing hormone analogue (GnRHa) and human growth hormone (GH) (8 girls) or with GnRHa alone (2 girls). After 4 years of treatment, height SDS for bone age was improved in the group who received combined treatment (from -0.97 to +0.07, p < 0.001), in contrast to the 2 patients who received GnRHa alone in whom height standard deviation scores for bone age decreased (from -1.10 to -1.33). Sitting height in all patients was relatively shorter than leg length, and there was no significant alteration during the 4 years of treatment.
Thomas
B C
BC
Medical Unit, Institute of Child Health, London, UK.
Stanhope
R
R
Leiper
A D
AD
D000365:Age Determination by Skeleton; D001827:Body Height / Q000187:drug effects; D001921:Brain / Q000528:radiation effects; D002648:Child; D002675:Child, Preschool; D005260:Female; D017273:Goserelin / Q000627:therapeutic use*; D013006:Growth Hormone / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000532:radiotherapy; D011629:Puberty, Precocious / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology
D017273:Goserelin; D013006:Growth Hormone